within Pharmacolibrary.Drugs.ATC.B;

model B03AA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.1,
    Cl             = 5e-05,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0005,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>B03AA05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Ferrous chloride is an iron salt used as a source of elemental iron for the prevention and treatment of iron-deficiency anemia. It is generally administered orally. It is not widely used today due to the preference for other ferrous salts such as ferrous sulfate, gluconate, or fumarate, which have better tolerability profiles.</p><h4>Pharmacokinetics</h4><p>No specific published pharmacokinetic models or parameters for ferrous chloride in humans could be identified. The following parameters are estimated based on known properties of ferrous salts and general iron oral supplementation PK. Parameters are for an average healthy adult.</p><h4>References</h4><ol><li><p>Rupin, A, et al., &amp; Verbeuren, TJ (2011). S35972, a direct-acting thrombin inhibitor with high oral bioavailability and antithrombotic efficacy. <i>Journal of thrombosis and haemostasis : JTH</i> 9(7) 1375–1382. DOI:<a href=\"https://doi.org/10.1111/j.1538-7836.2011.04286.x\">10.1111/j.1538-7836.2011.04286.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21481181/\">https://pubmed.ncbi.nlm.nih.gov/21481181</a></p></li><li><p>Chang, DE, et al., &amp; Edlich, RF (1988). Fatal transcutaneous iron intoxication. <i>The Journal of burn care &amp; rehabilitation</i> 9(4) 385–388. DOI:<a href=\"https://doi.org/10.1097/00004630-198807000-00013\">10.1097/00004630-198807000-00013</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3220852/\">https://pubmed.ncbi.nlm.nih.gov/3220852</a></p></li><li><p>Friel, JK, et al., &amp; Serfass, RE (2005). Iron absorption and oxidant stress during erythropoietin therapy in very low birth weight premature infants: a cohort study. <i>BMC pediatrics</i> 5 29–None. DOI:<a href=\"https://doi.org/10.1186/1471-2431-5-29\">10.1186/1471-2431-5-29</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/16080798/\">https://pubmed.ncbi.nlm.nih.gov/16080798</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end B03AA05;
